BioVie posts corporate presentation outlining bezisterim, BIV201 clinical programs in neurodegeneration, Long COVID, liver disease
BIVI•Corporate presentation outlines pipeline programs
BioVie highlighted bezisterim, an oral small molecule designed to modulate TNFα-driven inflammation across Parkinson’s disease, Long COVID, and Alzheimer’s disease.
Topline data is expected in 3Q 2026 for SUNRISE-PD Phase 2b in Parkinson’s disease and ADDRESS-LC Phase 2 in Long COVID.
Bezisterim showed a smaller mean worsening than placebo on MDS-UPDRS Part I-III and total in an ITT set of 57 patients.
BIV201, a continuous IV terlipressin formulation for ascites, was described as Phase 3-ready with an FDA-agreed design, Fast Track, and Orphan status.
Pipeline materials cited US annual sales potential of $3 billion for Parkinson’s, $10 billion for Long COVID, $30 billion for Alzheimer’s, and $1.6 billion for ascites.
